Resistant hypertension optimal treatment trial: A randomized controlled trial

Clinical Cardiology

Volumn 37, Issue 1, 2014, Pages 1-6

  Krieger, Eduardo M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CHLORTALIDONE; CLONIDINE; ENALAPRIL; LOSARTAN; SPIRONOLACTONE;

ADULT; ARTICLE; BLOOD PRESSURE; BRAZIL; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SLEEP DISORDERED BREATHING; SYMPATHETIC TONE;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAZIL; CALCIUM CHANNEL BLOCKERS; CLINICAL PROTOCOLS; CLONIDINE; DIURETICS; DRUG DISCOVERY; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PREVALENCE; RESEARCH DESIGN; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892611161     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22228     Document Type: Article

References (33)

1. Butler RN,. Living longer, contributing longer. JAMA. 1997; 278: 1372-1373.
2. Appel LJ,. Dietary patterns and longevity: expanding the blue zones. Circulation. 2008; 118: 214-215.
3. Drager LF, Lopes HF, Maki-Nunes C, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One. 2010; 5: e12065.
4. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011; 58: 811-817.
5. Howard BV, Rodriguez BL, Bennett PH, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: epidemiology. Circulation. 2002; 105: e132-e137.
6. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-1645.
7. Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008; 51: 339-344.
8. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51: 1403-1419.
9. Pimenta E, Calhoun DA,. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012; 125: 1594-1596.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
11. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988-2008. Circulation. 2011; 124: 1046-1058.
12. Persell SD,. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011; 57: 1076-1080.
13. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 898-902.
14. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125: 1635-1642.
15. Krumholz HM, Weintraub WS, Bradford WD, et al. Task force #2-the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. J Am Coll Cardiol. 2002; 40: 603-615.
16. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009; 53: 646-653.
17. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007; 49: 839-845.
18. Berecek KH, Farag A, Bahtiyar G, et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep. 2004; 6: 211-212.
19. Carl D, Sica DA,. Spironolactone use in resistant hypertension. Curr Hypertens Rep. 2007; 9: 297-298.
20. Taler SJ, Textor SC, Augustine JE,. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002; 39: 982-988.
21. Maciel RM, Spritzer N, Spritzer TS, et al. Treatment of diuretic-resistant arterial hypertension-crossed comparative study of verapamil and clonidine [in Portuguese]. Arq Bras Cardiol. 1981; 36 (suppl 1): 47-50.
22. Viera AJ, Hinderliter AL,. Evaluation and management of the patient with difficult-to-control or resistant hypertension. Am Fam Physician. 2009; 79: 863-869.
23. Sociedade Brasileira de Cardiologia-SBC; Sociedade Brasileira de Hipertensão-SBH; Sociedade Brasileira de Nefrologia-SBN. V Brazilian guidelines in arterial hypertension [in Portuguese]. Arq Bras Cardiol. 2007; 89: e24-e79.
24. Che Q, Schreiber MJ Jr, Rafey MA,. Beta-blockers for hypertension: are they going out of style? Cleve Clin J Med. 2009; 76: 533-542.
25. Lindholm LH, Carlberg B, Samuelsson O,. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366: 1545-1553.
26. Laragh JH, Letcher RL, Pickering TG,. Renin profiling for diagnosis and treatment of hypertension. JAMA. 1979; 241: 151-156.
27. Zweifler A, Esler M,. Blood pressure, renin activity and heart rate changes during propranolol therapy of hypertension. Am J Cardiol. 1977; 40: 105-109.
28. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999; 131: 485-491.
29. Liao D, Barnes RW, Chambless LE, et al. Age, race, and sex differences in autonomic cardiac function measured by spectral analysis of heart rate variability-the ARIC Study. Am J Cardiol. 1995; 76: 906-912.
30. Drager LF, Genta PR, Pedrosa RP, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol. 2010; 105: 1135-1139.
31. Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012; 30: 1656-1664.
32. Václavík J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011; 57: 1069-1075.
33. Mancia G., Additional drug treatment in resistant hypertension: need for randomized studies. J Hypertens. 2012; 30: 1514-1515.